Aberdeen, UK – [27th March 2016] As Europe’s leading biopartnering and investment conference, BioTrinity brings together investors, pharmaceutical executives and innovative life science R&D companies, from around the world. To mark BioTrinity’s 10th anniversary the new Perfect Pitch session has been introduced to their London meeting to increase the number of ways biotechnology companies can connect with potential investors and corporate partners.
From an original list of 104 show-case companies, 10 company CEO’s were originally selected to delivered investment pitches to half a dozen seasoned investors. From this short-list, a final 4 companies were selected to pitch again. The winner was Dr Caroline Barelle CEO of Elasmogen Ltd, a new-spin out from the University of Aberdeen.
Elasmogen spun out in Feb 2016 and to date has raised £2.8 M in grant and equity funding to commercialise its soloMER drugs and in particular its pipeline of auto-immune products in pre-clinical development for inflammatory eye and gut diseases.
Dr Barelle said about her success: “I was delighted and a little surprised to be selected to present as we are such a young company. To go on and win in front of a distinguished panel of investors’ shows just how far the team has come in such a short period of time. Our primary objective at Elasmogen is to develop sight-saving therapies for patients that suffer with an inflammatory eye disease called Uveitis. In particular we are focussing our effects on a population of Uveitis patients that are refractory to current therapies and who will almost certainly go on to develop irreversibly loss of part or all of their sight. Unlike other therapies
that are injected into patients our soloMER technology will allow topical, site-specific delivery directly into the eye, maximising their efficacy and minimising any harmful side-effects.”
About Elasmogen’s technology
soloMER technology exploits the power of biologics (proteins) as drugs but in a small, 1/12 the size of an antibody, stable format that enables site specific delivery through complex and challenging environments like the eye and gut. Unique to Elasmogen, and protected by a portfolio of granted patents, soloMERs are pre-disposed to generating potent neutralisers by binding in a unique way to drug targets. Their small size, shows the potential for site-specific delivery to the eye but Elasmogen is also developing them, in collaboration with others, to penetrate and kill solid cancer tumours.
For further information please contact:
Dr Caroline Barelle – CEO
caroline.barelle@elasmogen.com
Elasmogen
Elasmogen Limited (‘Elasmogen’ or the ‘Company’) is a private, UK-based biologics focused biopharmaceutical company. The Company has a late stage pre-clinical product portfolio of assets (soloMERs™ targeting large and important markets with significant unmet clinical needs.
The research and development portfolio includes ELN/21 and ELN/22 for the treatment of auto-inflammatory eye disease including a novel multi-active and sight-saving orphan therapy for refractory or corticosteroid resistant uveitis. In addition, ELN/11 for the treatment of solid tumours a potential blockbuster in partnership with Almac Discovery Ltd
The Company is also developing earlier stage compounds from its proprietary platforms for the site specific delivery of soloMERs to and importantly into cells.
